Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00288353 · ClinicalTrials.gov registry record · Phase 3
Estimating and Reducing the Cardiovascular Risk of Patients With Schizophrenia Drugs From Lipid Measures and Ischemic Electrocardiographic Changes
A Phase 3 study, sponsored by Northwestern University.
- Terminated
- Registry status
- Phase 3
- Development phase
- 48
- Enrollment target
NCT00288353 is a Phase 3 study that was terminated before completion, run by Northwestern University. The registered enrollment target is 48 participants.
The verdict
NCT00288353, a Phase 3 study, was terminated before completion, sponsored by Northwestern University.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 48 participants
- Enrollment target
Study Summary
The primary goal of this study is to examine the triglyceride/high-density lipoprotein (TG/HDL) ratio and the ischemic EKG changes in patients with schizophrenia, schizoaffective disorder or bipolar disorder.
Interventions
- DRUG ziprasidone (Geodon)
- DRUG aripiprazole (Abilify)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2006-01 |
| Est. Completion | 2008-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00288353
The ClinicalTrials.gov registry entry for NCT00288353 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which ziprasidone (Geodon) is the first listed.
NCT00288353 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00288353 about?
NCT00288353 is a clinical study titled "Estimating and Reducing the Cardiovascular Risk of Patients With Schizophrenia Drugs From Lipid Measures and Ischemic Electrocardiographic Changes". The primary goal of this study is to examine the triglyceride/high-density lipoprotein (TG/HDL) ratio and the ischemic EKG changes in patients with schizophrenia, schizoaffective disorder or bipolar disorder.
What is the current status of trial NCT00288353?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 48 participants. The study started on 2006-01. Estimated completion is 2008-12.
What interventions are being tested in trial NCT00288353?
The interventions under investigation include: ziprasidone (Geodon) (DRUG), aripiprazole (Abilify) (DRUG).
Who is sponsoring clinical trial NCT00288353?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.